HYGEIA Hospital
ΛΗΤΩ Μαιευτικό, Γυναικολογικό & Χειρουργικό Κέντρο
Y-Logimed Α.Ε.
AlfaLab | Kέντρο Μοριακής Βιολογίας & Κυτταρογενετικής
Beatific® | Super-effective Anti-aging Skincare for Face - Eyes - Body


Συγγραφή Επιστημονικών Βιβλίων

Συγγράψαμε με τον Διευθυντή κ. Δ. ΠΟΛΥΖΩΓΟΠΟΥΛΟ (4η Κλινική Ν.Ν.Θ.Α.) τρίτομο σύγγραμμα Κλινικής Πνευμονολογίας (Σελ. 2.350 – Α’ Εκδοση 1993).

Nέα συγγραφή- Β’Εκδοση- 2005-Τόμοι 3- Σελίδες 3070

Μετέφρασα και επιμελήθηκα την έκδοση της «Ακτινοδιαγνωστικής Θώρακος και Καρδίας» του Καθηγητού R. EISENBERG και της «Βρογχοσκόπησης» του Καθηγητού STRADLING.-1996

ΦΥΣΙΟΛΟΓΙΑ ΤΟΥ ΑΝΑΠΝΕΥΣΤΙΚΟΥ-Μετάφραση του J.B. West «Respiratory Physiology», 1987

ΠΑΘΟΦΥΣΙΟΛΟΓΙΑ ΤΟΥ ΑΝΑΠΝΕΥΣΤΙΚΟΥ-Μετάφραση του J.B. West «Pulmonary Pathophysiology», 1986

Atlas of Bronchoscopy, edited by G. Thalassinos and V. Polychronopoulos, translated version of P. Stradling-1996

ΠΑΘΟΦΥΣΙΟΛΟΓΙΑ ΔΙΑΧΥΤΩΝ ΠΝ/ΘΕΙΩΝ-Εκδόσεις Ελλ.Πν/κής Εταιρείας 1994


ΒΡΑΔΕΩΣ ΛΥΟΜΕΝΗ ΠΝΕΥΜΟΝΙΑ— Εκδόσεις Ιατρικής Εταιρείας Αθηνών1990


ΑΕΡΙΣΜΟΣ ΠΝΕΥΜΟΝΩΝ-Εκδόσεις Ελληνικής Πνευμ/κής Εταιρείας 1991

ΔΙΑΓΝΩΣΤΙΚΗ ΚΑΙ ΕΠΕΜΒΑΤΙΚΗ ΒΡΟΓΧΟΣΚΟΠΗΣΗ-Μεταπτυχιακό Σεμινάριο Ελλ. Πν/κής Εταιρ, 1996


OΡΓΑΝΟΥΜΕΝΗ ΠΝΕΥΜΟΝΙΑ-Εκδόσεις Ελλ. Πν. Εταιρείας 2004


Polychronopoulos V., Kosmas E. Pleural effusion secondary to Gastrointestinal Disease. In: Deckers Pleural Disease; Bouros D: 2004-and 2nd Edition 2008

Same as 16 : 3rd Edition, 2010

ΠΝΕΥΜΟΝΙΚΗ ΚΥΚΛΟΦΟΡΙΑ- Εκδόσεις Ελληνικής Πνευμ/κής Εταιρείας 2006

Εξωγενής Αλλεργική Κυψελιδίτις-Εκδόσεις Ελληνικής Πνευμ/κής Εταιρείας-2007

Οξέα Διάμεσα και Κυψελιδικά Νοσήματα-Εκδόσεις Ελλ.Πνευμ. Εταιρ. 2008

Η Κλινική Αξιολόγηση των Εργ/κών ευρημάτων στις Διάχυτες Πνευμονοπάθειες-Ελληνική Πνευμ/κή Εταιρεία 2009.

Συχνές Ερωτήσεις στην Πνευμονολογία-Εκδόσεις Ελλ. Πν.Ετ. –ΠΝΕΥΜΟΝΙΚΗ ΕΜΒΟΛΗ-2010.

Diffuse Alveolar Hemorrhage syndromes: chapter 15;E.Stagaki and V.Polychronopoulos;In:S.K.Jindal’s:Textbook of Pulmonary and Critical Care Medicine;JAYPEE Brothers;2010—  2nd Edition : JAYPEE Brothers; 2015

Airway involvement in ILDs:S.Tryphon,V.Polychronopoulos,in:  Interstitial Lung Disease;O.Sharma;ED.JAYPEE Brothers,2011

Acute Exacerbation of Sarcoidodis;In:.Acute Exacerbation of Respiratory Disease: S.SAHN;ED. :JAYPEE Brothers,2011

1. Respiratory and lower limb muscle function in interstitial lung disease. Panagiotou M1, Polychronopoulos V2, Strange C3,Chron Respir Dis. 2016 Jan 14–

2. The Effect of Incidental Consolidation on Management and Outcomes in COPD Exacerbations: Data from the European COPD Audit.

3. Saleh A, López-Campos JL, Hartl S, Pozo-Rodríguez F,Roberts CM;PolychronopoulosV.et al: European COPD Audit team.-

4. PLoS One. 2015 Jul 27;10(7):e0134004. doi: 10.1371/journal.pone.0134004. eCollection 2015

5. Innate immunity alterations in idiopathic interstitial pneumonias and rheumatoid arthritis-associated interstitial lung diseases.
6. Papanikolaou IC1, Boki KA2, Giamarellos-Bourboulis EJ3, Kotsaki A4, Kagouridis K5, Karagiannidis N6, Polychronopoulos VS7. Immunol.Lett.2014;Dec;2014
7. A prospective study on bacterial and atypical etiology of acute exacerbation in chronic obstructive pulmonary disease.
Nakou A1, Papaparaskevas J, Diamantea F, Skarmoutsou N, Polychronopoulos V, Tsakris A.
Future Microbiology;2014,November ,,1251

8. Prediction of Hospitalization Stay in COPD Exacerbations: The AECOPD-F Score. F.Diamantea, V.Polychronopoulos, A. Papaioannou et al:Resp.Care 2014, June

9. Collateral Damage: Depressive Symptoms in the Partners of COPD Patients.Papaioannou AI, Tsikrika S, Bartziokas K, Karakontaki F, Kastanakis E, Diamantea F, Haniotou A, Papiris S, Polychronopoulos V, Loukides S, Kostikas K.Lung. 2014 May 11

10. Concomitant sarcoidosis and a connective tissue disease: Review of the clinical findings and postulations concerning their association.

11. Judson MA, Shapiro L, Freitas S, Polychronopoulos VS, Highland KB. Resp. Med. Febr.2013

12. A case of tracheal hamartoma resected with loop electrocautery. Panagiotou M, Kalkanis A, Karagiannidis N, Polychronopoulos V. Case Rep Pulmonol. 2013;2013:568590. doi: 10.1155/2013/568590. Epub 2013 Jan 14.

13. Expression of hypoxia-inducible factor (HIF)-1a-vascular endothelial growth factor (VEGF)-inhibitory growth factor (ING)-4- axis in sarcoidosis patients.Tzouvelekis A, Ntolios P, Karameris A, Koutsopoulos A, Boglou P, Koulelidis A, Archontogeorgis K, Zacharis G, Drakopanagiotakis F, Steiropoulos P, Anevlavis S, Polychronopoulos V, Mikroulis D, Bouros D.BMC Res Notes. 2012 Nov 26;5:654. doi: 10.1186/1756-0500-5-654.

14. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good.Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L; European IPF Consensus Group.Thorax. 2012 Nov;67(11):938-40. doi: 10.1136/thoraxjnl-2012-202580. Epub 2012 Oct 9. No abstract available.

15. The impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbations.— 15 Citations-(Aug 2014)–Papaioannou AI, Bartziokas K, Tsikrika S, Karakontaki F, Kastanakis E, Banya W, Haniotou A, Papiris S, Loukides S, Polychronopoulos V, Kostikas K.Eur Respir J. 2012 Aug 9. [Epub ahead of print]
16. Decreased apoptotic rate of alveolar macrophages of patients with idiopathic pulmonary fibrosis.Drakopanagiotakis F, Xifteri A, Tsiambas E, Karameris A, Tsakanika K, Karagiannidis N, Mermigkis D, Polychronopoulos V, Bouros D.Pulm Med. 2012;2012:981730. doi: 10.1155/2012/981730. Epub 2012 Jun 25.

17. TREM-1 expression on neutrophils and monocytes of septic patients: relation to the underlying infection and the implicated pathogen.Poukoulidou T, Spyridaki A, Mihailidou I, Kopterides P, Pistiki A, Alexiou Z, Chrisofos M, Dimopoulou I, Drimoussis P, Giamarellos-Bourboulis EJ, Koutelidakis I, Marioli A, Mega A, Orfanos SE, Theodorakopoulou M, Tsironis C, Maggina N, Polychronopoulos V, Tsangaris I; Hellenic Sepsis Study Group.BMC Infect Dis. 2011 Nov 4;11:309. doi: 10.1186/1471-2334-11-309.

18. Prognostic value of C-reactive protein in parapneumonic effusions.Skouras V, Boultadakis E, Nikoulis D, Polychronopoulos V, Daniil Z, Kalomenidis I, Gourgoulianis KI.Respirology. 2012 Feb;17(2):308-14. doi: 10.1111/j.1440-1843.2011.02078.
19. .Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters.Papakosta D, Pitsiou G, Daniil Z, Dimadi M, Stagaki E, Rapti A, Antoniou K, Tzouvelekis A, Kontakiotis T, Tryfon S, Polychronopoulos V, Bouros D.Lung. 2011 Oct;189(5):391-9. doi: 10.1007/s00408-011-9304-5. Epub 2011 Jun 11.

20. Impact of multidrug resistance on experimental empyema by Pseudomonas aeruginosa.Giamarellos-Bourboulis EJ, Tzepi I, Tsovolou I, Spyridaki A, Tsaganos T, Vaki I, Kotsaki A, Polychronopoulos V.Respiration. 2011;82(1):46-53. doi: 10.1159/000326893. Epub 2011 Apr 28.

21. Procalcitonin as an early indicator of outcome in sepsis: a prospective observational study.—22 Citations—Aug.2014Giamarellos-Bourboulis EJ, Tsangaris I, Kanni T, Mouktaroudi M, Pantelidou I, Adamis G, Atmatzidis S, Chrisofos M, Evangelopoulou V, Frantzeskaki F, Giannopoulos P, Giannikopoulos G, Gialvalis D, Gourgoulis GM, Kotzampassi K, Katsifa K, Kofinas G, Kontopidou F, Koratzanis G, Koulouras V, Koutsikou A, Koupetori M, Kritselis I, Leonidou L, Mega A, Mylona V, Nikolaou H, Orfanos S, Panagopoulos P, Paramythiotou E, Papadopoulos A, Papanikolaou X, Pavlaki M, Polychronopoulos V, Skoutelis A, Theodotou A, Vassiliaghou M, Douzinas EE, Gogos C, Armaganidis A; Hellenic Sepsis Study Group.J Hosp Infect. 2011 Jan;77(1):58-63. doi: 10.1016/j.jhin.2010.07.026. Epub 2010 Dec

22. Cryptogenic and secondary organizing pneumonia: clinical presentation, radiographic findings, treatment response, and prognosis.—28 Citations—(Aug.2014)Drakopanagiotakis F, Paschalaki K, Abu-Hijleh M, Aswad B, Karagianidis N, Kastanakis E, Braman SS, Polychronopoulos VChest. 2011 Apr;139(4):893-900. doi: 10.1378/chest.10-0883. Epub 2010 Aug 19.

23. Acute exacerbations of interstitial lung diseases. Papanikolaou IC, Drakopanagiotakis F, Polychronopoulos VS.Curr Opin Pulm Med. 2010 Sep;16(5):480-6. doi: 10.1097/MCP.0b013e32833ae49d. Review.

24. How common is sleep-disordered breathing in patients with idiopathic pulmonary fibrosis? 20 Citations—Aug 2014 Mermigkis C, Stagaki E, Tryfon S, Schiza S, Amfilochiou A, Polychronopoulos V, Panagou P, Galanis N, Kallianos A, Mermigkis D, Kopanakis A, Varouchakis G, Kapsimalis F, Bouros D.Sleep Breath. 2010 Dec;14(4):387-90. doi: 10.1007/s11325-010-0336-5. Epub 2010 Mar 16.

25. Airway involvement in sarcoidosis. 31 Citations Aug 2014– Polychronopoulos VS, Prakash UB.Chest. 2009 Nov;136(5):1371-80. doi: 10.1378/chest.08-2569. Review.

26. Chapter: Diffuse alveolar hemorrhage. Karakontaki Foteini, Stagaki E, Polychronopoulos V
In:Textbook of Pulmonary and Critical Care Medicine. Jaypee Brothers 2016

27. Cardiovascular comorbidities in hospitalised COPD patients: a determinant of future risk?Papaioannou AI, Bartziokas K, Loukides S, Tsikrika S, Karakontaki F, Haniotou A, Papiris S, Stolz D, Kostikas K.Eur Respir J. 2015 Apr 16.

28. Prediction of hospitalization stay in COPD exacerbations: the AECOPD-F score Diamantea F, Kostikas K, Bartziokas K, Karakontaki F, Tsikrika S, Pouriki S, Polychronopoulos V, Karagiannidis N, Haniotou A, Papaioannou AI. Respir Care. 2014 Nov;59(11):1679-86.

29. Collateral damage: depressive symptoms in the partners of COPD patients. Papaioannou AI, Tsikrika S, Bartziokas K, Karakontaki F, Kastanakis E, Diamantea F, Haniotou A, Papiris S, Polychronopoulos V, Loukides S, Kostikas K. Lung. 2014 Aug;192(4):519-24.

30. Impact of Hemodialysis on Dyspnea and Lung Function in End Stage Kidney Disease Patients Anastasios F. Palamidas, Sofia-Antiopi Gennimata, Foteini Karakontaki, Georgios Kaltsakas, Ioanis Papantoniou, Antonia Koutsoukou, Joseph Milic-Emili, Demetrios Vlahakos and Nikolaos G. Koulouris BioMed Research International Volume 2014 , Article ID 212751, 10 pages

31. Driving-related neuropsychological performance in stable COPD patients. Foteini Karakontaki, Sofia-Antiopi Gennimata, Anastasios F Palamidas, Theocharis Anagnostakos, Epaminondas N Kosmas, Anastasios Stalikas, Charalambos Papageorgiou and Nikolaos G Koulouris. Pulmonary Medicine; Vol 2013: Article ID 297371, 10 pages

32. Prediction of postoperative lung function and chronic dyspnea in lung cancer patients by using quantitative computed tomography CV Papageorgiou, Dimosthenis Antoniou, Georgios Kaltsakas, Foteini Karakontaki, Panagiotis Misthos, Iris Tsangaridou, Loukas Thanos, NG Koulouris. Science Journal of Clinical Medicine July 2013; 2(4): 134-140

33. The impact of depressive symptoms on recovery and outcome of hospitalized COPD exacerbations. Papaioannou A, Bartziokas K, Tsikrika S, Karakontaki F, Kastanakis E, Banya W, Haniotou A, Papiris S, Loukides S, Polychronopoulos V, Kostikas K. Eur Respir J 2013; 41:815-823

34. Pathophysiology of evolution of small airway disease to overt COPD Gennimata SA, Palamidas A, Karakontaki F, Kosmas EN, Koutsoukou A, Loukides S, Koulouris NG COPD 2010;7(4):269-75

35. Pulmonary thromboembolic disease. Review article. Stagaki Ε, Apostolakis S, Karakontaki F, Tsaramisli Μ, Polychronopoulos V, Konstaninides S.Hellenic Journal of cardiology 2012; 530:159-173

36. Therapeutic dilemma in anti-TB treatment. Strouvalis Ι, Karakontaki F, Tsaramisli M, Diamantea F, Karagiannidis N. Pneumon, December 2009;76-78

37. Skouras VS, Kalomenidis I. Pleural fluid tests to diagnose tuberculous pleuritis. Curr Opin Pulm Med, 2016;22: [Epub ahead of printing]

38. Skouras VS, Kalomenidis I. Effusions caused by drugs. In: Textbook of pleural diseases, 3rd edition. Editors: Light RW, Lee YCG. Taylor & Francis Group, Boca Raton, FL, 2016; p.p. 386-396

39. Skouras VS, Magkouta S, Psallidas I, Tsilioni I, Maragozidis P, Gourgoulianis KI, Kalomenidis I. Interleukin-27 improves the ability of adenosine deaminase to rule-out tuberculous pleural effusion regardless of pleural tuberculosis prevalence. Infect Dis (Lond), 2015;47(7):477-83

40. Skouras VS, Pastis NJ, Polychronopoulos V, Silvestri GA. Mediastinal staging in lung cancer. The quest for a cost-effective strategy. Pneumon, 2014;27(1):16-31

41. Skouras VS, Tanner NT, Silvestri GA. Diagnostic approach to the solitary pulmonary nodule. Semin Respir Crit Care Med, 2013;34(6):762-9

42. Psathakis K, Skouras V, Chatzivassiloglou F, Tsintiris K. Osteophytes may be a rare cause of recurrent pleural effusions. Monaldi Arch Chest Dis, 2013;79(2):87-9

43. Skouras V, Boultadakis E, Nikoulis D, Polychronopoulos V, Daniil Z, Kalomenidis I, Gourgoulianis KI. Prognostic value of C-reactive protein in parapneumonic effusions. Respirology, 2012;17(2):308-14

44. Σκούρας Β, Αντωνογιαννάκη Μ. Ο βήχας στα διάμεσα νοσήματα του πνεύμονος. Στο: Κλινικά φροντιστήρια – Διαφοροδιάγνωση χρόνιου βήχα. Συντάκτες: Λουκίδης Σ. Εκδόσεις: Ιατρική Εταιρεία Αθηνών, Αθήνα 2012;24(3):32-51

45. Σκούρας Β, Αντωνογιαννάκη ΜΕ, Πανσεληνάς Ε, Πολυχρονόπουλος Β. Κλινικά συμπτώματα και ευρήματα. Στο: Άτλαντας Ογκολογίας Θώρακα. Συντάκτες: Συρίγος Κ, Γκιόζος Γ, Χαρπίδου Α. Αθήνα, Εκδόσεις Παρισιάνου, 2012: 133-140

46. Boultadakis V, Skouras V, Makris D, Damianaki A, Nikoulis DJ, Kiropoulos T, Oikonomidi S, Tsilioni I and Gourgoulianis K. Serum amyloid alpha in parapneumonic effusions. Mediators Inflamm, 2011:237638. Epub 2011 Aug 25

47. Brixey AG, Luo Y, Skouras V, Awdankiewicz A, Light RW. The efficacy of chest radiographs in detecting parapneumonic effusions. Respirology. 2011 Aug;16(6):1000-4

48. Psathakis K, Skouras V. Blind needle biopsy of the pleura: why not? Eur Respir Rev, 2011;20(120):120-2

49. Gogos C, Kotsaki A, Pelekanou A, et al. Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Crit Care, 2010 May 26;14(3):R96

50. Σκούρας Β. Διαγνωστική προσέγγιση υπεζωκοτικής συλλογής. Στο: Κλινικά φροντιστήρια – Διαγνωστική προσέγγιση αναπνευστικών προβλημάτων για τον μη ειδικό. Συντάκτες: Μιχαηλίδης Σ, Πολυχρονόπουλος Β. Εκδόσεις: Ιατρική Εταιρεία Αθηνών, Αθήνα 2010;22(2):94-122

51. Skouras V, Kalomenidis I. Chylothorax: diagnostic approach. Curr Opin Pulm Med, 2010;16:387-393

52. Skouras V, Awdankiewicz A, Light RW. What size parapneumonic effusions should be sampled? Thorax, 2010;65(1):91

55. Ther Adv Respir Dis. 2008 Jun;2(3):141-8.Control of asthma. Zervas E, Oikonomidou E, Kainis E, Kokkala M, Petroheilou K, Gaga M.